HomeBUSINESS
BUSINESS

Daiichi Sankyo Winds Up Deal on Thrombus Dissolving Agent amid Re-Prioritization Drive
(Dec.5.2017)

Daiichi Sankyo said on December 1 that it will return all development and commercialization rights for Translational Sciences’ thrombus dissolving agent TS23 as part of its portfolio re-prioritization efforts despite a successful PI trial ...
(LOG IN FOR FULL STORY)